Avivagen secures large order for OxC-beta ™ cattle in Asia

OTTAWA, Ontario, October 18, 2021– (BUSINESS WIRE) – Avivagen Inc. (TSXV: VIV, OTCQB: VIVXF) (“Avivagen”), a life science company focused on the development and commercialization of products for livestock, companion animals and human applications that safely improve food intake and support immune function, thereby supporting overall health and performance, is pleased to announce the signing of a major new purchase contract to supply its larger customer in Asia an order for 6.3 tonnes of OxC-beta ™ Livestock. Shipping represents a 43% increase in size from the customer’s previous order and continues a trend of increasing order sizes with this customer and other OxC-beta ™ customers around the world.

“We are extremely pleased to see the continued growth of this important customer in Asia, one of the most important regions in the world for the production of animal feed,” said Kym Anthony, CEO of Avivagen Inc. ” We believe that the fact that Avivagen customers continue to increase the volume of their OxC-beta ™ orders in the context of a global pandemic is a clear sign of the positive impact that the integration of our products can have on customers. results of our clients. We are excited about the growth potential that awaits us in Asia and around the world. “

About Avivagen
Avivagen is a life sciences company focused on the development and commercialization of products for livestock, companion animals and humans that, by safely supporting immune function, promote general health and performance. It is a public company listed on the TSX Venture Exchange under the symbol VIV and headquartered in Ottawa, Canada, at the partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The content of the website is expressly not incorporated by reference in this press release.

About OxC-beta ™ technology and OxC-beta ™ breeding
Avivagen’s OxC-beta ™ technology is derived from Avivagen’s findings on β-carotene and other carotenoids, compounds that give certain fruits and vegetables their vivid colors. By supporting immune function, the technology provides a non-antibiotic way to promote health and growth. OxC-beta ™ Livestock is a proprietary product that has proven to be an effective and economical alternative to antibiotics commonly added to livestock feed. The product is currently available for sale in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Brazil, Australia and Malaysia.

Avivagen’s OxC-beta ™ livestock product is safe, effective and may fulfill the global mandate to eliminate all antibiotics in the diet as growth promoters. Numerous international poultry and pig trials using OxC-beta ™ Livestock have proven that the product works as well, and sometimes in some ways better than antibiotics in feed.

Forward-looking statements
This press release includes certain forward-looking statements based on management’s current expectations. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the company operates. All statements contained in this document that are not statements of historical fact can be considered as forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “Could”, “estimate”, “expect”, “if”, “intend”, “objective”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “continue”, “appear”, “should”, “if”, “will”, “would” and similar expressions. Statements in this press release regarding future plans of Avivagen customers and the potential for additional and / or increased orders from these customers, expected growth in demand for Avivagen products, expected date of completion of the command described, the possibility of OxC-beta ™ Livestock to replace antibiotics in feed as well as to meet a critical need for sanitary support in certain livestock applications where antibiotics are excluded and the size of the opportunities for market are all forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties which could cause actual results or events to differ materially from current expectations. For example, the order described may not result in new orders for Avivagen products, customer plans may change for many reasons, demand for Avivagen products may not continue to grow and may decline. , Avivagen’s products may not be accepted by the market or approved by authorities in new jurisdictions or for new applications, including human applications, and may not be widely accepted as substitutes for antibiotics in feeds. , a new market entry may not occur within the time or in the manner intended by Avivagen, the lead time of the order may be delayed beyond current expectations for a number of reasons which would delay fulfillment and the recognition of revenue from this order in a future quarter or, in the worst case, would result in the termination of the order and market opportunities p may not be as important as Avivagen anticipates, in each case due to many factors, many of which are beyond Avivagen’s control. Readers are referred to the risk factors associated with Avivagen’s business as set out in the most recent Avivagen MD&A and Financial Condition Analysis available at www.SEDAR.com. Except as required by law, Avivagen assumes no obligation to update any forward-looking statements or to update the reasons why actual results could differ from those reflected in forward-looking statements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Copyright © 2021 Avivagen Inc. OxC-beta ™ is a trademark of Avivagen Inc.

See the source version on businesswire.com: https://www.businesswire.com/news/home/202111018005216/en/


Avivagen Inc.
Drew basek
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Telephone: 416-540-0733
Email: [email protected]

Kym Antoine
Chief Executive Officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Head office phone: 613-949-8164
Website: www.avivagen.com

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *